Logge Warren B, Haber Paul S, Hurzeler Tristan P, Towers Ellen E, Morley Kirsten C
Edith Collins Centre for Translational Research in Alcohol, Drugs and Toxicology, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW, Australia.
Specialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia.
Psychopharmacology (Berl). 2025 Jan;242(1):149-160. doi: 10.1007/s00213-024-06656-z. Epub 2024 Aug 5.
N-acetyl cysteine (NAC) is a potential pharmacotherapy for alcohol use disorder (AUD), but it is not known whether it modulates neural activation to alcohol cues or intrinsic functional connectivity. We investigated whether NAC attenuates (i) alcohol cue-elicited activation, and (ii) intrinsic functional connectivity compared to placebo in patients with AUD. In this preliminary study, twenty-three individuals (7 females) with moderate-severe AUD received daily NAC (2400 mg/day, n = 9), or a placebo (n = 14) for at least 2 weeks. Participants completed a pre-treatment functional magnetic resonance imaging session (T0) and a post-treatment session (T1) comprising resting-state and visual alcohol cue reactivity task acquisitions. Activation differences between sessions, treatment, and session-by-treatment interaction were assessed. Resting-state functional connectivity examined using 377 node ROI-to-ROIs evaluated whether NAC reduced intrinsic functional connectivity after treatment. There were no differences in alcohol cue reactivity for brain activation or subjective craving between NAC and placebo during treatment or across sessions, or significant interaction. A significant treatment-by-time interaction, with reduced intrinsic connectivity was observed after treatment (T1) for NAC-treated compared to placebo-treated patients in the posterior cingulate node (9, left hemisphere) of the dorsal attentional network and connections to salience, ventral-attentional, somatosensory, and visual-peripheral networks implicated in AUD. NAC reduced intrinsic functional connectivity in patients with moderate-severe AUD after treatment compared to placebo, but did not attenuate alcohol cue-elicited activation. However, the absence of cue reactivity findings may result from low power, rather than the absence of cue reactivity findings associated with NAC. These results provide preliminary evidence that NAC treatment may modulate intrinsic functional connectivity brain activation in patients with alcohol use disorder, but replication in larger studies are required to determine the strength of this effect and any associations with clinical outcomes. Clinical Trials Registration: ClinicalTrials.gov Identifier: NCT03879759.
N-乙酰半胱氨酸(NAC)是一种用于治疗酒精使用障碍(AUD)的潜在药物疗法,但尚不清楚它是否能调节对酒精线索的神经激活或内在功能连接。我们研究了与安慰剂相比,NAC是否能减轻(i)酒精线索引发的激活,以及(ii)AUD患者的内在功能连接。在这项初步研究中,23名患有中度至重度AUD的个体(7名女性)每天接受NAC(2400毫克/天,n = 9)或安慰剂(n = 14)治疗至少2周。参与者完成了一次治疗前的功能磁共振成像检查(T0)和一次治疗后的检查(T1),包括静息态和视觉酒精线索反应任务采集。评估了各检查之间、治疗组之间以及检查与治疗组交互作用之间的激活差异。使用377个节点的感兴趣区域(ROI)到ROI来检查静息态功能连接,以评估NAC治疗后是否降低了内在功能连接。在治疗期间或不同检查之间,NAC和安慰剂在大脑激活的酒精线索反应或主观渴望方面没有差异,也没有显著的交互作用。与安慰剂治疗的患者相比,NAC治疗的患者在背侧注意网络的后扣带回节点(9,左半球)以及与AUD相关的突显、腹侧注意、体感和视觉外周网络的连接中,观察到治疗与时间的显著交互作用,即治疗后(T1)内在连接性降低。与安慰剂相比,NAC治疗后中度至重度AUD患者的内在功能连接性降低,但并未减轻酒精线索引发的激活。然而,未发现线索反应结果可能是由于统计功效不足,而非NAC不存在相关线索反应结果。这些结果提供了初步证据,表明NAC治疗可能调节酒精使用障碍患者的内在功能连接性脑激活,但需要在更大规模的研究中进行重复验证,以确定这种效应的强度以及与临床结果的任何关联。临床试验注册:ClinicalTrials.gov标识符:NCT03879759。